+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

M

Actively Recruiting

Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.

Age: 55Years - 95YearsAll GendersPhase 2Phase 3
154 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of MH002, a live biotherapeutic product made of live bacteria, for treating mild-to-moderate ulcerative colitis UC. This condition causes inflammation and sores in the gut. The study aims to confirm previous findings and test two different doses of MH002 to understand its long-term effects on UC patients who have not fully responded to standard 5-aminosalicylic acid 5-ASA treatment. Participants will be randomly assigned to one of three groups low-dose MH002, high-dose MH002, or placebo. Both doses of MH002 consist of six wildtype commensal bacterial strains and are given orally once daily in capsule form. The study will last at least 12 weeks, focusing on the induction phase, during which researchers will monitor treatment effects and safety. During the study, participants will undergo assessments including endoscopic exams to measure changes in the gut lining, histologic evaluations, fecal calprotectin tests, and symptom scores to assess disease activity. Safety and tolerability will also be closely monitored. The primary outcome is the change in Mayo Endoscopic Subscore at Week 12. Participants will be followed throughout the treatment phase, which helps researchers understand how MH002 affects UC over time.

Age: 16Years +All GendersPhase 2
49 locations